The COVID-19 pandemic posed significant risk to the health of cancer patients,
compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic …

The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid
structural changes in healthcare delivery, with many positive changes likely to continue long …

The process of developing new anticancer therapeutics has been considered by some to be
expensive, 1 time consuming, 2 bureaucratic, 3 and, to some extent, inefficient. 4 The …

UKCCMP delivers meaningful real-time data to all UK cancer centres and clinicians to allow
more personalised approaches to individual patient care and inform clinical decision …

The COVID-19 pandemic affected many activities in the healthcare system including
oncology drug development. Clinical trial recruitment was temporary halted in many centres …

The impact of the COVID-19 pandemic on health services in the UK and around the world
cannot be understated. Cancer care services, patient and cancer research communities …

Simple Summary The SARS-CoV-2 pandemic led to a significant disruption to healthcare.
Cancer Trials Ireland is the national cooperative cancer trials organisation in Ireland. We …

The declaration of the coronavirus disease 2019 (COVID-19) as a pandemic by the World
Health OrganizationonMarch11, 2020, hasledtounprecedentedmeasures such as social …

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry,
Government, and Regulatory Agency Perspective | Cancer Discovery | American Association …

The coronavirus disease-19 (COVID-19) pandemic promises to have lasting impacts on
cancer clinical trials that could lead to faster patient access to new treatments. In this article …